Accredited Official Statistics
All data contained within this publication are Accredited Official Statistics, with the exception of Breast Cancer Referrals data.
Published by: Information & Analysis
Directorate, Department of Health
Statisticians: Brian Reilly, Thomas Cash & Sally
Pattison
Contact: statistics@health-ni.gov.uk
Reporting Period: 1 April 2024 - 30 June 2024
Publication Date: 26 September 2024
Date of Next Publication: 9 January 2025
Coverage: Northern Ireland
Frequency: Quarterly
On 9 November 2023 the South Eastern Health and Social Care (HSC) Trust launched ‘encompass’ - a new electronic patient record system. The system also went live in Belfast HSC Trust on 6 June 2024 and its rollout across the other Trusts will follow on a phased basis throughout 2024/25. Given the relatively recent transition of Belfast HSC Trust, no data were available for this Trust at the time of publication.
The data provided for South Eastern HSC Trust are sourced from encompass and are considered to be ‘official statistics in development’, which are a subset of Official Statistics in line with the Code of Practice for Statistics. While caution must be exercised when using these figures, they are a meaningful representation of what they measure and are of sufficient quality for publication and use.
Charts and figures presented throughout this report do not include Belfast HSC Trust data. This is to allow comparisons to be made for the four other HSC Trusts over previous years. As such, any Northern Ireland level figures throughout this report only include data for Northern, South Eastern, Southern and Western HSC Trusts.
This statistical release presents information on waiting times for cancer services at hospitals in Northern Ireland and reports on the performance of the Health and Social Care Trusts against the draft waiting time targets which state that:
Information is detailed on the number of patients who began treatment by HSC Trust for all targets and by tumour site for the 31 and 62 day targets. All of the data contained in this release are published in Excel file format to facilitate secondary analysis. This file is available at the following link:
Figures in this section do not include the Belfast HSC Trust as validated data were not available for this Trust at the time of publication. 31 and 62 Day Target data for the HSC Trusts have been revised due to the ongoing development and evaluation of data sourced from encompass.
• In the quarter ending June 2024, 1,629 patients started their first definitive treatment, 7.7% (135) fewer than in the previous quarter (1,764), and 5.6% (96) fewer than in the same quarter last year (1,725).
• 91.4% (1,489) of those patients started treatment within 31 days of a decision to treat, compared with 90.9% (1,603) in the previous quarter and 91.9% (1,585) in the same quarter last year.
• In the quarter ending June 2024, 894.5 patients started their first definitive treatment, 8.7% (85) fewer than in the previous quarter (979.5), and 14.8% (155) fewer than in the same quarter last year (1,049.5).
• 35.8% (320) of those patients started treatment within 62 days, compared with 33.8% (331.5) in the previous quarter and 39.4% (414) in the same quarter last year.
• In the quarter ending June 2024, there were 3,019 patients seen by a breast cancer specialist following an urgent referral for suspect breast cancer, 11.3% (306) more than in the previous quarter (2,713), and 10.7% (293) more than in the same quarter last year (2,726).
• 30.7% (928) of those patients were seen within 14 days of their urgent referral for breast cancer, compared with 36.1% (980) in the previous quarter and 62.4% (1,700) in the same quarter last year.
Figures in this section do not include the Belfast HSC Trust as validated data were not available for this Trust at the time of publication. 31 Day Target data for the HSC Trusts have been revised due to the ongoing development and evaluation of data sourced from encompass.
Target: At least 98% of patients urgently referred with a suspected cancer should begin their first definitive treatment within 31 days of a decision to treat.
In the quarter ending June 2024, 1,629 patients started
treatment following a decision to treat, of which 91.4% (1,489) started
treatment within 31 days. The target was not achieved at a regional
level.
The number of patients starting treatment decreased by 7.7% (135) since last quarter, and decreased by 5.6% (96) from the same quarter last year.
The percentage of patients starting treatment within 31 days increased slightly from 90.9% in the previous quarter and decreased from 91.9% in the same quarter last year.
No HSC Trust met the target of 98% percent of patients starting treatment within 31 days.
Figures in this section do not include the Belfast HSC Trust as validated data were not available at the time of publication.
Of tumour sites with more than 50 patients in the Northern, South Eastern, Southern and Western HSC Trusts starting treatment during the quarter ending June 2024, Haematological Cancers had the highest percentage treated within 31 days (100.0%) while Skin Cancers had the lowest (79.9%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 31 Days | % Within 31 Days change since last quarter |
---|---|---|---|---|
Skin Cancers | 369 | -17 | 79.9% | -0.4 |
Breast Cancer | 315 | 20 | 91.4% | 2.6 |
Urological Cancer | 256 | -85 | 99.2% | 1.3 |
Lower Gastrointestinal Cancer | 215 | -23 | 90.2% | 1.6 |
Haematological Cancers | 151 | -9 | 100.0% | 1.9 |
Lung Cancer | 105 | 8 | 100.0% | 0.0 |
Upper Gastrointestinal Cancer | 67 | -18 | 98.5% | -1.5 |
Head/Neck Cancer | 59 | -3 | 93.2% | -3.6 |
Gynaecological Cancers | 58 | 4 | 82.8% | 1.3 |
Other | 17 | -3 | 100.0% | 5.0 |
Sarcomas | 11 | 1 | 90.9% | 0.9 |
Brain/Central Nervous System | 5 | -8 | 100.0% | 0.0 |
Site Not Recorded | 1 | -2 | 100.0% | 33.3 |
Figures in this section do not include the Belfast HSC Trust as validated data were not available for this Trust at the time of publication. 62 Day Target data for the HSC Trusts have been revised due to the ongoing development and evaluation of data sourced from encompass.
Target: At least 95% of patients urgently referred by a GP with suspected cancer should begin their first definitive treatment within 62 days.
During the quarter ending June 2024, 894.5 patients started treatment following an urgent GP referral for suspect cancer, of which 35.8% (320) started treatment within 62 days.
The number of patients treated decreased by 8.7% (85) since last quarter, and decreased by 14.8% (155) since the same quarter last year.
The percentage of patients starting treatment within 62 days increased from 33.8% in the previous quarter and decreased from 39.4% in the same quarter last year.
The Western HSC Trust reported the highest percentage of patients starting treatment within 62 days at 43.0% (114.5 of 266).
The lowest percentage was reported by the Southern HSC Trust at 25.5% (49 of 192).
Figures in this section do not include the Belfast HSC Trust as validated data were not available at the time of publication.
Of tumour sites with more than 50 patients in the Northern, South Eastern, Southern and Western HSC Trusts starting treatment during the quarter ending June 2024, Haematological Cancers had the highest percentage treated within 62 days (68.3%) while Lower Gastrointestinal Cancer had the lowest (12.6%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 62 Days | % Within 62 Days change since last quarter |
---|---|---|---|---|
Skin Cancers | 223.0 | -12.5 | 40.1% | 1.3 |
Urological Cancer | 206.0 | -68 | 25.0% | 3.8 |
Breast Cancer | 139.0 | 12.5 | 46.4% | 3.7 |
Lower Gastrointestinal Cancer | 119.0 | 1 | 12.6% | -11.1 |
Haematological Cancers | 50.5 | 8 | 68.3% | 11.8 |
Gynaecological Cancers | 40.0 | -3.5 | 31.2% | 11.7 |
Lung Cancer | 36.5 | -11.5 | 63.0% | 9.9 |
Upper Gastrointestinal Cancer | 36.0 | -6 | 36.1% | -7.9 |
Head/Neck Cancer | 32.5 | -3.5 | 29.2% | -19.4 |
Other | 10.0 | 1 | 70.0% | 25.6 |
Sarcomas | 2.0 | -2.5 | 0.0% | -44.4 |
Figures in this section do not include the Belfast HSC Trust as validated data were not available for this Trust at the time of publication.
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Target: All urgent breast cancer referrals should be seen within 14 days.
During the quarter ending June 2024, 3,019 patients were seen by a breast cancer specialist following an urgent referral, of which 30.7% (928) were seen within 14 days.
The number of patients seen increased by 11.3% (306) from last quarter, and increased by 10.7% (293) from the same quarter last year.
The percentage of patients seen within 14 days decreased from 36.1% in the previous quarter and decreased from 62.4% in the same quarter last year.
No HSC Trust achieved the target of seeing all urgent breast cancer referrals within 14 days. Western HSC Trust saw the highest percentage of patients within 14 days (82.6%).
Revised: Figure 3 and Table 5 were amended on 17 October 2024 to include revised 31 March 2024 data for Western HSC Trust and NI (excl. Belfast) in the time series.
Figures in this section do not include the Belfast HSC Trust as validated data were not available for this Trust at the time of publication.
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Adding the number of referrals for suspect breast cancer at each HSC Trust to make a Northern Ireland total may inflate the ‘true demand’ on the service regionally as any referrals transferred from one Trust to another will create a duplicate referral.
During the quarter ending June 2024, 4,939 referrals were received by HSC Trusts for suspect breast cancer, of which 67.7% (3,346) were classified as urgent.
During the quarter ending June 2024, the highest number of referrals (1,674) were received by the Northern HSC Trust for suspect breast cancer, of which 46.4% (776) were classified as urgent. The South Eastern HSC Trust received the lowest number of breast cancer referrals (1,008), and 80.0% (806) of these were urgent referrals.
The total of 4,939 breast cancer referrals represents approximately 4,768 individual patients referred for breast cancer treatment during the quarter ending June 2024.
Approximately 3.6% of patients (170 out of 4,768) across the Northern, Southern, South Eastern and Western HSC Trusts were referred more than once for breast cancer treatment during the quarter ending June 2024.
A patient may be referred more than once if they are transferred to another consultant or a different Trust, or if they did not attend first treatment appointment and have been referred again.
Data used to report on the 31 and 62 day targets are sourced from the Cancer Patient Pathway System (CaPPS), the data system used to administer cancer treatment services within Health and Social Care Trusts in Northern Ireland.
Data used to report on the breast cancer activity and referrals are sourced from the Patient Administration System (PAS), an administrative system used to manage, record and monitor hospital waiting lists within Health and Social Care Trusts in Northern Ireland. Hospital Information Branch introduced this methodology for the collection of breast cancer waiting time information in April 2017. Information was originally sourced from the Departmental SDR2 Return in aggregate format.
Data for the South Eastern HSC Trust from 9 November 2023 onwards are sourced from ‘encompass’, which is a new electronic patient record system. These data are considered to be ‘official statistics in development’. The system also went live in Belfast HSC Trust on 6 June 2024 and its rollout across the other Trusts will follow on a phased basis throughout 2024/25.
Regionally consistent data collection for cancer waiting times has been in place since April 2008. Cancer referrals data has been collected from April 2016.
All data presented in this publication have been validated and quality assured by Hospital Information Branch in conjunction with HSC Trusts.
The 31 day target relates to all patients who received a first definitive treatment for cancer during each of the three months covered in the publication, irrespective of their source or type of referral.
This is measured from the date on which the patient and the clinician agree the planned treatment and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
The 62 day target relates to patients who received a first definitive treatment for cancer during each of the three months covered in the publication, following an urgent referral for suspect cancer from a General Practitioner (GP) or a routine GP referral that has subsequently been reclassified as urgent by a cancer specialist. Referrals from sources other than a GP, routine referrals and patients who have not been given an ICD 10 diagnosis are excluded.
This is measured from the date an initial urgent GP referral for suspect cancer is received by the HSC Trust and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
Prior to June 2009, the target relating to waiting time for treatment following an urgent GP referral for suspect cancer was that at least 75% of patients urgently referred with a suspect cancer should begin their first definitive treatment within 62 days of referral.
Breast cancer activity reported against the 14 day target relates to all urgent referrals for suspect breast cancer that were first seen during each of the three months covered in the publication, irrespective of the source of referral. Figures include routine referrals that have subsequently been reclassified by a breast specialist as urgent and exclude urgent referrals reclassified as routine.
This is measured from the date an initial breast cancer referral is first received by the HSC Trust, and ends on the date that the patient attends their first outpatient appointment with a breast cancer specialist. Adjustments are made to the completed waiting time in the event of a patient cancelling, self-deferring or failing to attend a first outpatient appointment.
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Figures provided in the Breast Cancer Referrals section reflect all new referrals received for suspect breast cancer irrespective of the source or urgency of referral. Referrals for breast cancer can be for advice, assessment or both.
The measurement of a patient’s waiting time against the 62 day target includes cases in which a patient was initially referred to one Trust for consultant assessment but was then subsequently transferred to another Trust for treatment. In such cases, the responsibility for that patient is shared, with 0.5 allocated to the Trust where the patient was first assessed and 0.5 to the Trust of first treatment. For example, if a patient is initially referred for assessment in the Southern HSC Trust and is then transferred to the Belfast HSC Trust where they receive treatment 70 days after their initial GP referral, both the Southern and Belfast HSC Trusts will report 0.5 of a patient treated who waited over 62 days.
For the 31 day target, all patients are reported against the Trust providing their treatment.
Breast cancer activity is reported against the Trust the patient is referred to.
Breast cancer referrals are reported against the Trust the patient is referred to. However, as some referrals will be transferred to another Trust, this referral can be recorded under both the intial Trust and the Trust that has accepted transfer of the patient.
The 31 and 62 day targets relate to patients who received a first definitive treatment for cancer having been given an ‘International Classification of Diseases 10’ (ICD 10) diagnosis. Patients that have not been given an ICD 10 diagnosis are excluded.
Tumour sites are assigned by aggregation of applicable ICD 10 codes.
Data for all cancers are included except for basal cell carcinoma.
A breakdown of these statistics by Trust and tumour site is not routinely published due to the relatively small number of patients involved and disclosure control needed to preserve the privacy of individual patients.
These statistics include patients living outside Northern Ireland and privately funded patients seen in Health and Social Care hospitals in Northern Ireland.
Technical guidance and definitions, as well as notes on how to use the date contained within this statistical release are available at the following link:
https://www.health-ni.gov.uk/publications/cancer-waiting-times-guidance-and-returns
Data detailed in this publication are also available in Excel file format to aid secondary analysis.
XLSX files are available to download at the following link: https://www.health-ni.gov.uk/publications/northern-ireland-waiting-time-statistics-cancer-waiting-times-april-june-2024.
Statistics on waiting times for inpatients, outpatients, diagnostic services and emergency care are available at the following link: https://www.health-ni.gov.uk/topics/doh-statistics-and-research/hospital-waiting-times-statistics
Accredited Official Statistics are called National Statistics in the Statistics and Registration Service Act 2007. These official statistics were independently reviewed by the Office for Statistics Regulation (OSR) in 2011. They comply with the standards of trustworthiness, quality and value in the Code of Practice for Statistics and should be labelled ‘Accredited Official Statistics’ (designation awarded in December 2013).
Our statistical practice is regulated by the OSR, which sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to.
You are welcome to contact us directly with any comments about how we meet these standards.
Alternatively, you can contact OSR by emailing regulation@statistics.gov.uk or via the OSR website Office for Statistics Regulation (https://osr.statisticsauthority.gov.uk).
It is the Department of Health’s responsibility, as the producer, to maintain compliance with the standards expected of Accredited Official Statistics. If we become concerned about whether these statistics are still meeting the appropriate standards, we will discuss any concerns with the OSR promptly. Accredited Official Statistics status can be removed at any point when the highest standards are not maintained and reinstated when standards are restored.
Find out more about the Code of Practice for Statistics at: https://code.statisticsauthority.gov.uk/
Find out more about Official Statistics at: https://uksa.statisticsauthority.gov.uk/about-the-authority/uk-statistical-system/types-of-official-statistics/
Please contact Hospital Information Branch for assistance with accessibility requirements or alternative formats. Email: statistics@health-ni.gov.uk
This publication is Crown copyright and may be reproduced free of charge in any format or medium. Any material used must be acknowledged, and the title of the publication specified.